FierceBiotech23h
Caris scores FDA approval for multi-cancer companion diagnostic test
across solid tumors with high microsatellite instability status as well as for Keytruda combined with Eisai and Merck’s ...
MedPage Today1d
Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy
Median overall survival (OS) increased from 19.3 months with upfront immune checkpoint inhibition (ICI) to 41.3 months when a ...
Targeted Oncology3d
The Targeted Pulse: A Review of Last Month’s FDA Prominent Actions and Key Data Updates Advancing Treatment Across Disease Types
According to data from the phase 3 double-blinded, active-controlled, multicenter LEAP-012 trial (NCT04246177), lenvatinib (Lenvima) with pembrolizumab (Keytruda) and transarterial chemoembolization ...